Search results for Dalotuzumab

Dalotuzumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade, ProteoGenix, PX-TA1239

Description of Dalotuzumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade Dalotuzumab Biosimilar: A Novel Anti-IGF1R Antibody for Targeted Cancer Therapy Dalotuzumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a cell surface receptor that plays a crucial role in cell growth and proliferation, making it an attractive therapeutic target for cancer treatment. Dalotuzumab Biosimilar is a research-grade version of the original dalotuzumab, which has shown promising results in clinical trials as a potential cancer therapy. Structure of Dalotuzumab Biosimilar Dalotuzumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from human antibodies and has been modified to reduce its immunogenicity. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of 12-14 days in humans. The binding site of dalotuzumab biosimilar is located on the extracellular domain of IGF1R, specifically targeting the α-subunit of the receptor. This binding site has been designed to block the binding of IGF1 and IGF2, the natural ligands of IGF1R, thereby inhibiting the activation of downstream signaling pathways involved in cancer cell growth and survival. Mechanism of Action IGF1R is overexpressed in many types of cancer, including breast, lung, and colorectal cancer. This overexpression has been linked to increased cell proliferation, angiogenesis, and resistance to chemotherapy. By targeting IGF1R, dalotuzumab biosimilar aims to inhibit these processes and induce cancer cell death. Upon binding to IGF1R, dalotuzumab biosimilar blocks the interaction between the receptor and its ligands, preventing the activation of downstream signaling pathways such as PI3K/AKT and MAPK/ERK. These pathways are important for cell survival and proliferation, and their inhibition by dalotuzumab biosimilar leads to decreased cancer cell growth and increased apoptosis. Application of Dalotuzumab Biosimilar Dalotuzumab biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including breast, lung, and colorectal cancer. In a phase II clinical trial for metastatic colorectal cancer, patients who received dalotuzumab in combination with chemotherapy showed a significant improvement in progression-free survival compared to those who received chemotherapy alone. Furthermore, dalotuzumab biosimilar has also been studied in combination with other targeted therapies, such as cetuximab, in patients with advanced non-small cell lung cancer. The combination showed promising results, with a higher response rate and longer progression-free survival compared to cetuximab alone. Future Directions As dalotuzumab biosimilar continues to show promising results in clinical trials, it is expected to become an important addition to the arsenal of targeted cancer therapies. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of various types of cancer. In addition, further research is being conducted to explore the potential of dalotuzumab biosimilar in other therapeutic areas, such as diabetes and growth disorders. Its ability to specifically target IGF1R makes it a potential candidate for the treatment of these diseases. Conclusion Dalotuzumab biosimilar, a novel anti-IGF1R antibody, has shown promising results in clinical trials as a potential cancer therapy. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of various types of cancer. As research continues, dalot

Dalotuzumab, Abbexa, abx831193

Dalotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.

Dalotuzumab ELISA Kit, ProteoGenix, KPTX158

Description of Dalotuzumab ELISA Kit Introduction Dalotuzumab is a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). This antibody has shown promising results in preclinical and clinical studies, making it a potential therapeutic option for various types of cancer. The Dalotuzumab ELISA Kit is a widely used tool for measuring the levels of this antibody in biological samples. In this article, we will discuss the structure, activity, and application of the Dalotuzumab ELISA Kit. Structure of Dalotuzumab Dalotuzumab is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the IGF-1R, while the constant region mediates the effector functions of the antibody. Activity of Dalotuzumab The main mechanism of action of Dalotuzumab is the inhibition of the IGF-1R signaling pathway. The IGF-1R is a transmembrane receptor that plays a crucial role in cell growth, proliferation, and survival. Overexpression of this receptor has been observed in various types of cancer, making it an attractive therapeutic target. Dalotuzumab binds to the IGF-1R and blocks the binding of its natural ligands, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2). This results in the inhibition of downstream signaling pathways, leading to decreased cell proliferation and increased cell death. Application of Dalotuzumab ELISA Kit The Dalotuzumab ELISA Kit is a highly sensitive and specific tool for measuring the levels of Dalotuzumab in various biological samples, such as serum, plasma, and cell culture supernatants. This kit utilizes the sandwich ELISA method, where the antibody is captured by a coated plate and detected by a specific enzyme-labeled antibody. The amount of bound antibody is then quantified by measuring the enzymatic activity of the labeled antibody. The Dalotuzumab ELISA Kit has several applications in the field of cancer research. It can be used to monitor the pharmacokinetics of Dalotuzumab in clinical trials, providing valuable information on the drug’s distribution, metabolism, and elimination. This kit can also be used to measure the levels of Dalotuzumab in patient samples, which can help in patient stratification and monitoring of treatment response. Additionally, the Dalotuzumab ELISA Kit can be used in preclinical studies to evaluate the efficacy of this antibody in different cancer models. Advantages of Using Dalotuzumab ELISA Kit The Dalotuzumab ELISA Kit offers several advantages over other methods of measuring antibody levels. It is a highly sensitive and specific assay, with a detection limit of as low as 0.1 ng/mL. This allows for accurate quantification of Dalotuzumab even at low concentrations. Moreover, this kit is easy to use and provides results within a short period of time, making it a convenient option for high-throughput experiments. The use of this kit also eliminates the need for radioactive or toxic reagents, making it safe for laboratory personnel and the environment. Conclusion In conclusion, the Dalotuzumab ELISA Kit is a valuable tool for measuring the levels of this promising therapeutic antibody. Its high sensitivity, specificity, and convenience make it a preferred choice for researchers and clinicians. With its ability to accurately measure Dalotuzumab levels in various biological samples, this kit has the potential to contribute to the development of this antibody as a novel cancer treatment.

Dalotuzumab ELISA Kit, Abbexa, abx395047

Dalotuzumab ELISA Kit is a quantitative ELISA kit for detection of Dalotuzumab.Dalotuzumab (MK-0646; h7C10), being developed by Merck & Co Inc under license from Pierre Fabre SA, is a recombinant humanized IgG1 mAb against the IGFR1 for the potential intravenous treatment of cancer. Preclinical studies have demonstrated that dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGFR1 autophosphorylation and Akt phosphorylation. In multiple cancer cell lines and in mouse xenograft models, dalotuzumab displayed significant antitumor activity, in particular against NSCLC and breast cancer. In addition, coadministration of dalotuzumab with other anticancer agents, such as taxanes, enhanced the in vitro and in vivo antitumor activity of dalotuzumab. Preliminary data from phase I clinical trials suggest that dalotuzumab is safe, well tolerated and significantly inhibits tumor proliferation. At the time of publication, several clinical trials evaluating dalotuzumab, alone and in combination with other anticancer agents, were ongoing in patients with various types of solid tumor and in patients with multiple myeloma. Although preliminary results appear promising, only future clinical and translational data will clarify the best clinical setting and treatment combinations for the optimal use of dalotuzumab in clinical practice.

Dalotuzumab Biosimilar - Research Grade, ichor.bio, ICH5463

Research Grade Dalotuzumab (HY353016), abinScience, HY353016